A Phase II Study of Combined VEGF Inhibitor (Bevacizumab + Sorafenib) in Patients With Metastatic Breast Cancer: Hoosier Oncology Group Study BRE06-109

For full description, see www.clinicaltrials.gov.

Manuscripts/Articles:

• Mina L, Yu M, Johnson C, Burkhardt C, Miller KD, Zon R. A phase II study of combined VEGF inhibitor (bevacizumab+sorafenib) in patients with metastatic breast cancer: Hoosier Oncology Group Study BRE06-109. Invest New Drugs (2013) 31:1307–1310 DOI 10.1007/s10637-013-9976-1. See abstract.